Product
LY4052031
1 clinical trial
13 indications
Indication
Metastatic Solid TumorIndication
Recurrent Solid TumorIndication
Advanced Solid TumorIndication
Bladder CancerIndication
Triple-Negative Breast CancerIndication
Lung CancerIndication
Esophageal cancerIndication
Pancreatic CancerIndication
Ovarian CancerIndication
Cervical CancerIndication
Head and Neck Squamous Cell CarcinomaIndication
Prostate CancerIndication
Renal Pelvis CancerClinical trial
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2027-05-01